Information Provided By: 
Fly News Breaks for October 6, 2016
INCY, PRTA, NBIX, ALNY
Oct 6, 2016 | 05:38 EDT
Barclays analyst Geoff Meacham downgraded Alnylam Pharmaceuticals (ALNY) to Equal Weight saying he views other SMid cap biotech names as more attractive following the company's recent pipeline setbacks. The analyst removed Revusiran sales from his Alnylam model after the program was discontinued yesterday and he cut his price target for the shares to $50 from $85. Meacham lists Neurocrine (NBIX), Prothena (PTRA) and Incyte (INCY) as names he finds more attractive over the next 12 months. Alnylam is trading down 44% in pre-market trading to $39.25.
News For ALNY;NBIX;PRTA;INCY From the Last 2 Days
INCY
Apr 25, 2024 | 09:27 EDT
NBIX
Apr 24, 2024 | 09:36 EDT
